EsoBiotec is developing a technological platform for the in vivo engineering of T-cells and other immune effector cells to generate cell therapies, such as CARs and TCRs, inside the body of patients for the treatment of cancer.
- CEO and Founder: Jean-Pierre Latere
- CSO: Philippe Parone
- Location: Belgium
- Web: esobiotec.com